查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1997149

免疫肿瘤临床试验市场：依治疗方法、试验阶段、适应症、试验类型、申办者及病患入组划分－2026-2032年全球市场预测

Immuno-oncology Clinical Trials Market by Therapy Type, Trial Phase, Indication, Trial Type, Sponsor Type, Patient Enrollment - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年免疫肿瘤临床试验市值为 74 亿美元，预计到 2026 年将成长至 83.2 亿美元，复合年增长率为 14.81%，到 2032 年将达到 194.7 亿美元。

主要市场统计数据
基准年 2025 74亿美元
预计年份：2026年 83.2亿美元
预测年份 2032 194.7亿美元
复合年增长率 (%) 14.81%

对不断发展的免疫肿瘤临床试验环境进行简要概述，重点关注转化研究的成熟、多方合作和运作挑战。

在生物学知识、先进製造平台和日益精细的试验设计融合的推动下，免疫肿瘤学临床试验正进入加速创新阶段。过去十年，免疫调节疗法已从早期概念验证研究发展成为复杂的、多组、以生物标记为重点的试验，这些试验不仅关注临床疗效，还整合了转化终点。这一趋势反映了该领域的日益成熟，阐明作用机制、选择合适的患者、制定联合治疗策略以及相关的基础治疗方法，都决定了计画的可行性。

科学融合、製造创新和监管适应性如何重塑免疫肿瘤学的临床试验策略和治疗途径。

在科学突破、技术进步和不断变化的监管预期推动下，肿瘤免疫学领域正经历着一场变革。从机制上看，该领域正从查核点抑制剂）转向整合疗法，将过继性细胞疗法、疫苗、细胞激素调节和靶向溶瘤药物相结合，以克服抗药性并扩大有效人群。这种转变得益于对肿瘤微环境异质性、克隆动力学和免疫逃脱机制的更深入理解，这些理解共同促成了合理的联合治疗策略和更精准的患者选择。

评估美国于 2025 年实施的关税措施对临床试验物流、製造和跨境合作研究的营运和策略外溢效应。

美国2025年推出的定向关税政策，为依赖全球采购的材料、专用设备和跨境临床合作进行免疫肿瘤学试验的临床试验赞助者带来了重大的营运挑战。实验室试剂、辅助设备和某些生物製药成分的进口关税不断提高，正逐步增加复杂临床试验（尤其是依赖海外生产的试剂和一次性耗材的细胞疗法）的每位患者的成本。除了直接的成本影响外，关税还影响采购计画和库存策略，促使申办方和临床试验中心在其供应链中预留更充足的缓衝空间，以降低供应链中断的风险。

综合細項分析揭示了治疗方法类型、临床实验生命週期、临床适应症、申办者概况和策略影响方面的差异。

精细化的细分观点能够深入洞察治疗潜力、营运准备和临床检验三者相契合的领域。根据治疗方法类型，该领域涵盖细胞疗法、癌症疫苗、查核点抑制剂、细胞激素疗法和溶瘤病毒。细胞疗法再细分为CAR-T细胞疗法、NK细胞疗法和TCR-T细胞疗法；癌症疫苗包括树突细胞疫苗、DNA疫苗和胜肽疫苗。查核点抑制剂根据其标靶进行区分：CTLA-4、PD-1和PD-L1；细胞激素疗法包括干扰素疗法和白细胞介素-2。干扰素疗法再细分为干扰素-α和干扰素-γ。这种治疗方法分类系统突显了技术风险和生产复杂性，显示基于平台的细胞疗法需要广泛的供应链协调，而胜肽类疫苗和特定的查核点策略则更容易实现规模化生产。

透过评估美洲、欧洲、中东和非洲以及亚太地区的地理优势和营运权衡，优化临床实验顺序和临床实验选择。

由于每个地区都具有其独特的科学、监管和物流特征，这些特征会影响专案的可行性和证据获取速度，因此区域趋势持续影响临床试验策略和营运设计。在美洲，紧密的学术医疗中心网络、成熟的法规结构和完善的契约製造有利于临床试验生态系统的发展，这些因素共同支持着复杂的细胞和基因项目，并促进针对特定适应症的快速受试者招募。另一方面，在选择临床实验中心时，必须考虑支付方预期和核准后推广路径的区域差异，以确保后期证据与商业化计画相符。

检验了以平台为中心的创新者、中型生物技术公司、学术联盟和服务合作伙伴的策略行为，并确定了伙伴关係模式和营运优势。

免疫肿瘤学试验中的企业行为反映了平台导向创新者和适应症导向开发者之间的两极化，从而在生态系统中形成了互补的角色。大型製药企业往往优先考虑后期检验、全球监管策略和商业化准备，并在註册试验和全球供应链基础设施方面投入大量资金。中型生物技术公司通常专注于首次人体概念验证（PoC）和转化检验，利用适应性设计和生物标记筛选队列快速迭代作用机制和检验。同时，学术机构和联盟提供基础科学、研究者主导的临床试验以及早期讯号产生所需的特殊检测方法和患者群体。

为高阶主管提供切实可行的措施，以将科学重点与製造韧性、适应性测试设计、转化严谨性和策略伙伴关係相结合。

产业领导者必须采取实际措施，将科学研究机会转化为营运稳健的项目，从而高效能惠及病患并产生永续的证据。首先，应优先精简产品组合，重点在于作用机制的清晰度和营运可行性，并将资源集中于生物证据、可生产性和可行监管途径均符合要求的资产。其次，应投资于生产韧性，例如认证多家关键试剂供应商、扩大国内高敏感性原料的生产能力，以及在合约和预算中纳入紧急时应对计画。这些措施将有助于降低供应链中断带来的风险，并确保可预测的检测计画。

对用于建构临床、营运和监管方面可操作见解的资料来源、分析方法、专家检验程序和限制进行透明说明。

本报告整合了临床试验註册数据、同行评审的转化研究、监管指导文件以及对临床管理人员、生产专家和监管从业人员的直接访谈，从而构建了免疫肿瘤学临床试验的整体情况。资料整合着重于试验层面的属性，例如治疗方法、试验阶段、适应症、申办者类型、试验设计特征和研究中心地理分布，并辅以关于生产实践、供应链限制和伙伴关係结构的定性资讯。分析方法包括横断面比较以识别营运差异，对展示最佳实践的代表性项目进行案例研究，以及情境规划以评估政策变化和供应链中断的影响。

一项权威的综合分析重点阐述了科学、製造和监管策略如何共同作用，将转化潜力转化为永续的临床和患者影响。

总之，免疫肿瘤学临床试验生态系统的特点是科学创新、营运精细化和策略合作之间的动态互动。儘管治疗方法的进步为治疗血液肿瘤和固态肿瘤开闢了新的途径，但成功的转化研究需要技术复杂性和生产能力、监管前瞻性以及与以患者为中心的试验设计相一致。关税政策和供应链压力日益凸显了本地生产和稳健的供应商策略的重要性，而区域优势则决定了专案从概念验证（PoC）开始，到最终获得註册核准的检验的开展。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：免疫肿瘤临床试验市场（依治疗方法）

  • 细胞疗法
    • CAR-T
    • NK细胞疗法
    • TCR-T
  • 癌症疫苗
    • 树突细胞疫苗
    • DNA疫苗
    • 胜肽疫苗
  • 查核点抑制剂
    • CTLA-4抑制剂
    • PD-1抑制剂
    • PD-L1抑制剂
  • 细胞激素疗法
    • 干扰素疗法
      • α干扰素
      • 干扰素γ
    • 白细胞介素-2
  • 溶瘤病毒

第九章：依试验阶段分類的免疫肿瘤临床试验市场

  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段

第十章：免疫肿瘤临床试验市场：依适应症划分

  • 骨髓恶性肿瘤
    • 白血病
    • 淋巴瘤
    • 多发性骨髓瘤
  • 固体癌
    • 乳癌
    • 结肠癌
    • 肺癌
    • 恶性黑色素瘤

第十一章：按试验类型分類的免疫肿瘤临床试验市场

  • 干预类型
  • 观察性研究

第十二章：按申办方分類的免疫肿瘤临床试验市场

  • 学术机构
  • 生技公司
  • 联盟
  • 製药公司

第十三章：以病人入组人数分類的免疫肿瘤临床试验市场

  • 大规模
  • 中号
  • 小规模

第十四章：免疫肿瘤临床试验市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：免疫肿瘤临床试验市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章：免疫肿瘤临床试验市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国免疫肿瘤临床试验市场

第十八章：中国免疫肿瘤临床试验市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Charles River Laboratory
  • Clinipace Company
  • Eli Lilly and Company
  • ICON PLC
  • IQVIA
  • Novo Nordisk A/S
  • PAREXEL International Corporation
  • Pfizer Inc.
  • PRA Health Sciences
  • SGS SA
  • Syneos Health
  • Wuxi AppTec Inc.
Product Code: MRR-035590447475

The Immuno-oncology Clinical Trials Market was valued at USD 7.40 billion in 2025 and is projected to grow to USD 8.32 billion in 2026, with a CAGR of 14.81%, reaching USD 19.47 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.40 billion
Estimated Year [2026] USD 8.32 billion
Forecast Year [2032] USD 19.47 billion
CAGR (%) 14.81%

A concise synthesis of the evolving immuno-oncology trial environment highlighting translational maturation, multi-stakeholder collaboration, and operational imperatives for advancement

The immuno-oncology clinical trial landscape has entered a phase of accelerated innovation driven by converging biological insights, advanced manufacturing platforms, and increasingly sophisticated trial designs. Over the past decade, immune-modulating modalities have evolved from early proof-of-concept studies to complex, multi-arm, biomarker-enriched trials that integrate translational endpoints alongside clinical efficacy. This trend reflects a maturing field where mechanistic clarity, patient selection, and combination strategies determine program viability as much as the underlying therapeutic modality.

Translational science now underpins trial hypotheses more consistently, with companion diagnostics and deep immune monitoring embedded in protocols to enable adaptive decision-making. At the same time, sponsors are balancing the logistical and regulatory demands of cell- and gene-based interventions with the imperative to reduce time-to-clinic and scale manufacturing. As a result, cross-sector collaboration among academic centers, biotechnology firms, and large pharmaceutical organizations has intensified, with trial networks and consortiums forming to share expertise, standardize assays, and accelerate enrollment for rare indications.

Consequently, decision-makers must synthesize biological rationale, operational feasibility, and regulatory pathways to prioritize assets and trial designs. Strategic clarity around patient segmentation, end-point selection, and manufacturing resilience will be a differentiator for programs that advance beyond early-stage promise to durable clinical impact

How scientific convergence, manufacturing innovation, and regulatory adaptability are reshaping clinical trial strategies and therapeutic pathways in immuno-oncology

The immuno-oncology landscape is undergoing transformative shifts driven by scientific breakthroughs, technology diffusion, and evolving regulatory expectations. Mechanistically, the field is moving beyond single-agent checkpoint blockade toward integrated approaches that combine adoptive cell therapies, vaccines, cytokine modulation, and targeted oncolytics to overcome resistance and broaden responder populations. This transition is supported by enhanced understanding of tumor microenvironment heterogeneity, clonal dynamics, and immune evasion mechanisms, which collectively enable rational combination strategies and more precise patient selection.

Technological advances have also altered operational realities. Improvements in cell manufacturing, cryopreservation, and decentralized production modalities are reducing lead times and expanding the feasible geography for complex trials. Simultaneously, digital health tools for remote monitoring, decentralization of site responsibilities, and real-world data integration are increasing trial flexibility and patient retention. Regulatory pathways are adapting incrementally, with agencies signaling openness to adaptive designs, basket and umbrella studies, and conditional approval frameworks based on robust surrogate endpoints.

Financially, investment focus is shifting toward later-stage de-risked assets and platform technologies that can generate multiple clinical programs. As a result, strategic partnerships and platform licensing are becoming more common, enabling smaller innovators to access development capacity while larger sponsors diversify pipelines. The cumulative effect is a more intricate, collaborative, and efficient ecosystem, where scientific innovation and operational innovation co-evolve to expand therapeutic possibilities

Assessing the operational and strategic ripple effects of United States tariff measures introduced in 2025 on clinical trial logistics, manufacturing, and cross-border collaborations

The introduction of targeted tariff policies in the United States in 2025 has introduced a material operational consideration for sponsors conducting immuno-oncology trials that depend on globally sourced materials, specialized instruments, and cross-border clinical collaborations. Higher import duties on laboratory reagents, ancillary devices, and certain biologic components have incrementally increased the per-patient cost structure for complex trials, particularly for adoptive cell therapies that rely on reagents and single-use consumables often manufactured abroad. Beyond direct cost effects, tariffs influence procurement timelines and inventory strategies as sponsors and clinical sites adopt more conservative supply chain buffers to mitigate disruption risk.

In response, many organizations are accelerating localization of critical manufacturing steps and qualifying domestic suppliers for key inputs to reduce exposure to import fluctuations. This shift has implications for capital allocation, as sponsors invest in onshore contract manufacturing organizations, expand in-house process development capabilities, and renegotiate supplier contracts to include contingency clauses. As a result, trial budgets and site selection criteria are increasingly evaluated through a lens that combines clinical feasibility with supply chain resiliency.

Tariff-driven dynamics also affect collaborative models. International academic partnerships and multi-national trial networks face heightened administrative complexity in coordinating material transfers and aligning GMP specifications across jurisdictions. Consequently, sponsors are prioritizing regulatory harmonization, advanced planning for cross-border logistics, and early engagement with customs and trade specialists. While the near-term impact has been to elevate operational costs and timelines for some programs, the enforced emphasis on supply chain robustness is catalyzing long-term benefits in manufacturing redundancy and quality assurance that will inform program design and go-to-market planning going forward

Integrated segmentation analysis illuminating therapeutic modality distinctions, trial lifecycle differences, clinical indications, sponsor profiles, and enrollment scale implications for strategy

A granular segmentation lens yields actionable insight into where therapeutic promise aligns with operational readiness and clinical validation. Based on therapy type, the landscape encompasses adoptive cell therapies, cancer vaccines, checkpoint inhibitors, cytokine therapies, and oncolytic viruses, with adoptive cell therapies subdivided into CAR-T, NK cell therapy, and TCR-T while cancer vaccines include dendritic cell, DNA, and peptide approaches; checkpoint inhibitors remain differentiated by CTLA-4, PD-1, and PD-L1 targets, and cytokine efforts feature interferon therapies and interleukin-2 where interferon approaches are further specified by interferon alpha and interferon gamma. This therapeutic taxonomy clarifies technological risk and manufacturing complexity, showing that platform-based cell therapies require extensive supply chain coordination, whereas peptide vaccines and certain checkpoint strategies scale more readily.

Based on trial phase, programs span Phase I through Phase IV, with early-phase work dominated by exploratory biomarker integration and safety optimization and later-phase studies emphasizing registrational endpoints and payer-relevant outcomes. Based on indication, the portfolio splits between hematological malignancies and solid tumors; hematologic programs target leukemia, lymphoma, and myeloma while solid tumor efforts focus on breast, colorectal, lung cancers, and melanoma. This dichotomy reveals divergent patient-recruitment strategies and endpoint selection, as hematologic trials frequently rely on measurable disease markers and centralized labs, and solid tumor trials demand robust imaging cohorts and site differentiation.

Based on sponsor type, trials are sponsored by academic institutions, biotechnology companies, consortiums, and pharmaceutical companies, each bringing differing governance, operational scale, and access to patient networks. Based on trial type, the field divides into interventional and observational studies, with interventional designs driving therapeutic validation and observational cohorts generating real-world evidence. Finally, based on patient enrollment, trials range from small-scale, focused cohorts to medium and large-scale studies, a distribution that influences statistical design, site selection, and resource allocation. Together these segmentation lenses inform prioritization by aligning scientific hypotheses with executional capacity and strategic intent

Evaluating geographical strengths and operational trade-offs across the Americas, Europe Middle East & Africa, and Asia-Pacific to optimize trial sequencing and site selection

Regional dynamics continue to shape trial strategy and operational design, as each geography presents unique scientific, regulatory, and logistical attributes that influence program feasibility and speed to evidence. In the Americas, the trial ecosystem benefits from dense networks of academic medical centers, mature regulatory frameworks, and established contract manufacturing capacity, which together support complex cell- and gene-based programs and facilitate rapid cohort accrual for certain indications. Conversely, site selection decisions must account for regional variations in payer expectations and post-approval adoption pathways to ensure that late-stage evidence aligns with commercialization plans.

In Europe, Middle East & Africa, heterogeneity in regulatory processes, reimbursement pathways, and clinical infrastructure necessitates early regulatory engagement and protocol harmonization across countries. This region offers valuable opportunities for multinational enrollment in both rare hematologic indications and diverse solid tumor cohorts, but success depends on centralized data management and consistent assay standardization. Meanwhile, in the Asia-Pacific region, rising clinical research capacity, expanding biotech innovation hubs, and cost-effective manufacturing options present compelling advantages for both early-phase studies and larger, pragmatic trials. However, ethical review timelines, import-export logistics, and local manufacturing qualification must be integrated into program timelines.

Across regions, sponsors are employing hybrid trial models, leveraging decentralized elements where appropriate and aligning site responsibilities with regional strengths. Strategic regional sequencing-initiating proof-of-concept work in centers with deep translational expertise, then scaling into regions with high patient availability and manufacturing support-continues to be a dominant approach for programs aiming to optimize speed, cost, and evidentiary rigor

Examining strategic behaviors of platform-focused innovators, mid-size biotechs, academic consortia, and service partners to identify partnership models and execution strengths

Company behavior within immuno-oncology trials reflects a bifurcation between platform-oriented innovators and indication-focused developers, creating complementary roles in the ecosystem. Large pharmaceutical organizations tend to emphasize late-stage validation, global regulatory strategy, and commercialization readiness, investing heavily in registrational trials and global supply chain infrastructure. Mid-sized biotechnology companies often concentrate on first-in-human proof-of-concept and translational validation, leveraging adaptive designs and biomarker-enriched cohorts to rapidly iterate on mechanism and dose. Meanwhile, academic institutions and consortia provide foundational science, investigator-led trials, and access to specialized assays and patient populations that are critical for early signal generation.

Partnership models are increasingly sophisticated, ranging from co-development and joint governance to licensing arrangements where platform owners supply manufacturing and process expertise while partners drive clinical execution. Contract research organizations and contract manufacturing organizations play essential roles in scaling trials, particularly for cell- and gene-based modalities, where GMP compliance, chain-of-identity controls, and cold-chain logistics are paramount. Observed strategic behaviors include portfolio pruning-where companies prioritize fewer, higher-conviction programs-and platform consolidation, where single technological approaches are extended across multiple indications to capture development leverage.

Taken together, company-level insights suggest that sponsors who align clinical ambition with manufacturing capacity, regulatory strategy, and a clear partnership model tend to execute trials with greater predictability. Executives should therefore assess organizational strengths against the modality-specific demands of their pipeline and consider strategic alliances that mitigate operational risk while accelerating clinical validation

Practical, high-impact steps for executives to align scientific priorities with manufacturing resilience, adaptive trial design, translational rigor, and strategic partnerships

Industry leaders must take deliberate steps to convert scientific opportunity into operationally sound programs that reach patients efficiently and generate durable evidence. First, prioritize portfolio rationalization centered on mechanistic clarity and operational realism; focus resources on assets where biological rationale, manufacturability, and a feasible regulatory pathway align. Second, invest in manufacturing resilience by qualifying multiple suppliers for critical reagents, expanding domestic capacity for sensitive inputs, and embedding contingency planning into contracts and budgets. These measures reduce vulnerability to supply chain shocks and support predictable trial timelines.

Third, adopt flexible trial designs that integrate adaptive elements, biomarker-driven cohorts, and decentralized components where clinically appropriate. This approach accelerates learning, reduces unnecessary exposure, and improves patient access. Fourth, strengthen translational frameworks that couple protocol-design with robust immune monitoring and harmonized assays to generate interpretable mechanistic readouts that inform downstream decisions. Fifth, pursue selective partnerships: collaborate with academic centers for early translational depth, with specialized CMOs for manufacturing scale-up, and with experienced CROs for complex operational execution. Finally, ensure early payer and regulatory engagement to align evidentiary programs with reimbursement expectations and approval pathways, thereby smoothing the path from clinical proof to patient access.

By executing these imperatives in concert, leaders can reduce development risk, compress timelines, and enhance the probability that promising immuno-oncology interventions translate into meaningful clinical and commercial outcomes

Transparent description of data sources, analytical techniques, expert validation steps, and limitations used to construct actionable insights across clinical, operational, and regulatory dimensions

This report synthesizes evidence from trial registries, peer-reviewed translational studies, regulatory guidance documents, and primary consultations with clinical operations leaders, manufacturing experts, and regulatory affairs practitioners to build a comprehensive view of the immuno-oncology trial landscape. Data integration emphasized trial-level attributes such as modality, phase, indication, sponsor type, trial design features, and site geography, augmented by qualitative input on manufacturing practices, supply chain constraints, and partnership structures. Analytical methods included cross-sectional comparisons to identify operational differentiators, case-based analysis of representative programs to illustrate best practices, and scenario planning to assess the effects of policy shifts and supply chain disruptions.

Quality assurance processes included triangulation across multiple independent sources, validation of protocol-level descriptions against sponsor disclosures, and expert review to ensure clinical and operational plausibility. Where proprietary datasets were used to augment public information, findings were presented at an aggregated level to preserve confidentiality while enabling actionable insight. Limitations of the methodology are acknowledged: rapidly evolving trial outcomes, emerging regulatory guidance, and real-time supply chain changes may alter operational calculus. To mitigate these limitations, recommended usage includes periodic updates and targeted deep dives focused on specific modalities or geographies. The methodological approach supports decision-makers by linking empirical trial attributes with executable operational recommendations and strategic pathways for program advancement

A decisive synthesis highlighting how aligned scientific, manufacturing, and regulatory strategies convert translational promise into sustainable clinical and patient impact

In conclusion, the immuno-oncology clinical trial ecosystem is characterized by a dynamic interplay between scientific innovation, operational sophistication, and strategic collaboration. Therapeutic advances are unlocking new avenues to address both hematologic and solid tumor indications, but successful translation depends on aligning technical complexity with manufacturing capability, regulatory foresight, and patient-centered trial design. Tariff policies and supply chain pressures have elevated the importance of localized manufacturing and robust supplier strategies, while regional strengths shape where programs initiate proof-of-concept work and where they scale to registrational validation.

Decision-makers should act with strategic focus: concentrate on high-conviction assets where translational rationale is supported by operational feasibility, establish partnerships that fill capability gaps, and adopt flexible trial designs that accelerate learning while managing risk. By integrating translational rigor with pragmatic operational planning and regional sequencing, sponsors can increase the probability that promising immuno-oncology approaches progress from experimental validation to meaningful clinical impact. The path forward requires coordinated investment across science, manufacturing, and trial design to ensure that therapeutic innovation reaches patients efficiently and sustainably

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Immuno-oncology Clinical Trials Market, by Therapy Type

  • 8.1. Adoptive Cell Therapies
    • 8.1.1. Car-T
    • 8.1.2. Nk Cell Therapy
    • 8.1.3. Tcr-T
  • 8.2. Cancer Vaccines
    • 8.2.1. Dendritic Cell Vaccines
    • 8.2.2. Dna Vaccines
    • 8.2.3. Peptide Vaccines
  • 8.3. Checkpoint Inhibitors
    • 8.3.1. Ctla-4 Inhibitors
    • 8.3.2. Pd-1 Inhibitors
    • 8.3.3. Pd-L1 Inhibitors
  • 8.4. Cytokine Therapies
    • 8.4.1. Interferon Therapies
      • 8.4.1.1. Interferon Alpha
      • 8.4.1.2. Interferon Gamma
    • 8.4.2. Interleukin-2
  • 8.5. Oncolytic Viruses

9. Immuno-oncology Clinical Trials Market, by Trial Phase

  • 9.1. Phase I
  • 9.2. Phase Ii
  • 9.3. Phase Iii
  • 9.4. Phase Iv

10. Immuno-oncology Clinical Trials Market, by Indication

  • 10.1. Hematological Malignancies
    • 10.1.1. Leukemia
    • 10.1.2. Lymphoma
    • 10.1.3. Myeloma
  • 10.2. Solid Tumors
    • 10.2.1. Breast Cancer
    • 10.2.2. Colorectal Cancer
    • 10.2.3. Lung Cancer
    • 10.2.4. Melanoma

11. Immuno-oncology Clinical Trials Market, by Trial Type

  • 11.1. Interventional
  • 11.2. Observational

12. Immuno-oncology Clinical Trials Market, by Sponsor Type

  • 12.1. Academic Institutions
  • 12.2. Biotechnology Companies
  • 12.3. Consortiums
  • 12.4. Pharmaceutical Companies

13. Immuno-oncology Clinical Trials Market, by Patient Enrollment

  • 13.1. Large Scale
  • 13.2. Medium Scale
  • 13.3. Small Scale

14. Immuno-oncology Clinical Trials Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Immuno-oncology Clinical Trials Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Immuno-oncology Clinical Trials Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Immuno-oncology Clinical Trials Market

18. China Immuno-oncology Clinical Trials Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Charles River Laboratory
  • 19.6. Clinipace Company
  • 19.7. Eli Lilly and Company
  • 19.8. ICON PLC
  • 19.9. IQVIA
  • 19.10. Novo Nordisk A/S
  • 19.11. PAREXEL International Corporation
  • 19.12. Pfizer Inc.
  • 19.13. PRA Health Sciences
  • 19.14. SGS SA
  • 19.15. Syneos Health
  • 19.16. Wuxi AppTec Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CAR-T, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CAR-T, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CAR-T, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY NK CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY NK CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TCR-T, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TCR-T, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TCR-T, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PEPTIDE VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PEPTIDE VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON ALPHA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON ALPHA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON ALPHA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON GAMMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON GAMMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON GAMMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERLEUKIN-2, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERLEUKIN-2, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERLEUKIN-2, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ONCOLYTIC VIRUSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ONCOLYTIC VIRUSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ONCOLYTIC VIRUSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MYELOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CONSORTIUMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CONSORTIUMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CONSORTIUMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LARGE SCALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LARGE SCALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LARGE SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MEDIUM SCALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MEDIUM SCALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MEDIUM SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SMALL SCALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SMALL SCALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SMALL SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2032 (USD MILLION)
  • TABLE 248. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2032 (USD MILLION)
  • TABLE 263. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 264. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 266. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 267. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 268. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 269. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 270. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 271. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 272. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 273. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 274. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR T